Apogee Therapeutics Announces Q2 Results for Quarter Ended June 30, 2026

What Happened

• On August 10, 2026, Apogee Therapeutics, Inc. filed a Form 8-K to announce a business update and its financial results for the quarter ended June 30, 2026. The company issued an earnings press release on the same date; that release is furnished as Exhibit 99.1 to the 8-K. The filing was signed by Michael Henderson, M.D., Chief Executive Officer.

Key Details

• Filing date: August 10, 2026 (Form 8-K furnished).
• Period reported: quarter ended June 30, 2026.
• Exhibit provided: Exhibit 99.1 — Earnings Press Release dated August 10, 2026.
• Form was signed by CEO Michael Henderson, M.D.

Why It Matters

• This 8-K signals that Apogee has released its latest quarterly results and business update; investors should review the earnings press release (Exhibit 99.1) for detailed metrics such as revenue, expenses, cash position, and any operational or clinical updates.
• Because the 8-K itself primarily furnishes the press release, the most relevant information for investment decisions—quarterly earnings figures, guidance changes, or specific operational disclosures—will be in that Exhibit.